SEC Comment Letter for Mereo BioPharma Group plc (MREO) (CIK 0001719714) (MREO) — Aug 24, 2022
Mereo BioPharma Group plc (MREO) (CIK 0001719714)
Date: Aug. 24, 2022 · CIK: 0001719714 · Accession: 0000000000-22-009122
AI Filing Summary & Sentiment
File numbers found in text: 001-38452
Letter
United States securities and exchange commission logo August 24, 2022 Christine Fox Chief Financial Officer Mereo Biopharma Group plc One Cavendish Place 4th Floor London, W1G 0QF United Kingdom Re:Mereo Biopharma Group plc Form 20-F for the Fiscal Year Ended December 31, 2021 Filed March 31, 2022 File No. 001-38452 Dear Ms. Fox: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
August 24, 2022
Christine Fox
Chief Financial Officer
Mereo Biopharma Group plc
One Cavendish Place 4th Floor
London, W1G 0QF
United Kingdom
Re:Mereo Biopharma Group plc
Form 20-F for the Fiscal Year Ended December 31, 2021
Filed March 31, 2022
File No. 001-38452
Dear Ms. Fox:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences